Praxis Precision Medicines, Inc. (PRAX) Stock
1 member of Congress disclosed 2 trades in PRAX since 2026: 2 purchases and 0 sales, most recently Gilbert Cisneros (purchase, Sep 29, 2026). 5 of the hedge funds AlphaScala tracks reported PRAX in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is Marshall Wace's at $45.87M.
Which members of Congress traded Praxis Precision Medicines, Inc. (PRAX)?
Most recent: Gilbert Cisneros (purchase, Sep 29, 2026); records start Jul 30, 2026.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Gil Cisneros D-CA · House | 2026-09-29 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-07-30 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026.
See all PRAX political trades →Which hedge funds own PRAX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Marshall Wace | 137K | $45.87M | +203% |
| Citadel Ken Griffin | 7K | $2.45M | NEW |
| D.E. Shaw David Shaw | 5K | $1.72M | NEW |
| Hussman Investment Trust John Hussman | 4K | $1.22M | n/a |
| Millennium Management Israel Englander | 995 | $333.1K | -74% |
13F holdings as of Sep 30, 2026
Explore all tracked funds →PRAX price chart
Powered by TradingViewWhat does Praxis Precision Medicines, Inc. do?
Praxis Precision Medicines Inc. operates within the biopharmaceutical sector, focusing on the development of treatments for central nervous system (CNS) disorders. The company's primary objective is to address unmet medical needs by leveraging their extensive research in genetics, the neurobiology of CNS disorders, and translational science. Praxis Precision Medicines is rapidly carving out a niche in the healthcare field by targeting illnesses such as epilepsy, movement disorders, and psychiatric conditions, which impact millions of individuals globally. Their innovative pipeline includes a variety of therapeutic candidates designed to modulate specific neural pathways that are believed to be core to CNS dysregulation. As an emerging leader in the biopharma industry, Praxis Precision Medicines plays a crucial role in advancing CNS treatment paradigms, working to improve quality of life for patients and expand the possibilities of personalized medicine through cutting-edge science.